How effective is bosentan in treating pulmonary hypertension?

Bosentan improves cardiopulmonary hemodynamics, exercise capacity, WHO functional class, and quality of life in patients with PAH, and delays clinical deterioration. Pulmonary hypertension is a severe progressive disease with significant morbidity and high mortality attributed to right heart failure. Bosentan, a dual endothelin receptor antagonist, is an effective and well-tolerated oral therapy for the treatment of pulmonary arterial hypertension (PAH; WHO category 1 pulmonary arterial hypertension).

Endothelin-1 is a potent vasoconstrictor and smooth muscle mitogen. In a pilot study, the oral dual endothelin receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension. This trial investigated the effect of bosentan on exercise capacity in a large number of patients and compared two doses.

In this double-blind, placebo-controlled study, 213 patients with pulmonary arterial hypertension (either primary or associated with connective tissue disease) were randomly assigned to receive placebo or 62.5 mg of bosentan twice daily for 4 weeks, followed by two doses of either bosentan (125 or 250 mg twice daily) for at least 12 weeks. The primary endpoint was the degree of change in exercise capacity. Secondary endpoints included change in Borg dyspnea index, change in World Health Organization (WHO) functional class, and time to clinical deterioration.

At Week 16 Six-minute walk distance improved in patients receiving bosentan; the mean difference between the placebo and bosentan combination groups was 44 m (95% confidence interval, 21 to 67; P<0.001). Bosentan also improved Borg dyspnea index and WHO functional class and prolonged time to clinical deterioration.

The endothelin receptor antagonist bosentan is beneficial in patients with pulmonary hypertension and is well tolerated at a dose of 125 mg twice daily. Oral bosentan antagonizes endothelin receptors and is an effective treatment for pulmonary hypertension.

Bosentan has shown good safety and tolerability in multiple studies. No patient withdrew from the study due to intolerable adverse effects. As a drug for the treatment of pulmonary arterial hypertension, bosentan has significant efficacy. It can improve patients' exercise tolerance, cardiac function, and reduce pulmonary artery pressure. It is suitable for patients with various types of pulmonary arterial hypertension and has good safety and tolerability.

Bosentan tablets have been launched in the domestic market and have been included in the scope of medical insurance reimbursement. Its specifications areFor 56 tablets of 125 mg, the price after medical insurance reimbursement is about 3,000 yuan. At the same time, we also learned that Indian cipla pharmaceuticals has launched a generic version of bosentan overseas, with a specification of 125ng and 20 tablets, and a price of about 400 yuan. The generic version of bosentan launched overseas is also well received by patients, and patients can choose according to their own needs.